Muscle wasting in heart failure: An overview

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 10, 2013, Pages 2257-2265

  Von Haehling, Stephan ^a,b   Steinbeck, Lisa ^a   Doehner, Wolfram ^a   Springer, Jochen ^a,b,c   Anker, Stefan D ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Cachexia; Heart failure; Mechanism; Muscle wasting; Sarcopenia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLENBUTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOTEROL; PERINDOPRIL; RECOMBINANT GROWTH HORMONE; TESTOSTERONE; VITAMIN D;

BLOOD FLOW; CHRONIC DISEASE; DISEASE ASSOCIATION; ENDOCRINE DISEASE; EXERCISE; HEART FAILURE; HUMAN; MUSCLE ATROPHY; MUSCLE METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; REVIEW; SARCOPENIA; SKELETAL MUSCLE; WALKING SPEED;

CACHEXIA; HEART FAILURE; MECHANISM; MUSCLE WASTING; SARCOPENIA;

ANIMALS; HEART FAILURE; HUMANS; MUSCULAR ATROPHY;

EID: 84885148465     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.04.02     Document Type: Review

References (87)

1. Adams V, Jiang H, Yu J., Möbius-Winkler S, Fiehn E, Linke A, Weigl C, Schuler G, Hambrecht R. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. Journal of the American College of Cardiology 1999; 33:959-65.
2. Allen DL, Yasui W, Tanaka T., Ohira Y, Nagaoka S, Sekiguchi C., Hinds WE, Roy RR, Edgerton VR Myonuclear number and myosin heavy chain expression in rat soleus single muscle fibers after spaceflight. Journal of Applied Physiology 1996; 81:145-51.
3. Anker SD, Swan JW, Volterrani M, Chua T.P., Clark AL, Poole-Wilson PA, Coats AJ The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. European Heart Journal 1997; 18:259-69.
4. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90:464-70.
5. Bailey JL, Wang X, England B.K., Price SR, Ding X, Mitch WE The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. Journal of Clinical Investigation 1996; 97:1447-53.
6. Bodine SC, Latres E, Baumhueter S., Lai VK, Nunez L, Clarke BA, Poueymirou W.T., Panaro FJ, Na E, Dharmarajan K, Pan Z.Q., Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-8.
7. Braga M, Bhasin S, Jasuja R., Pervin S, Singh R. Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action. Molecular and Cellular Endocrinology 2012; 350:39-52.
8. Busquets S, Toledo M, Orpí M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, López-Soriano FJ, Han HQ, Argilés JM. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle 2012; 3:37-43.
9. Cabello-Verrugio C, Córdova G, Salas JD. Angiotensin II: role in skeletal muscle atrophy. Current Protein and Peptide Science 2012; 13:560-9.
10. Cicoira M, Davos CH, Francis D.P., Doehner W., Zanolla L, Franceschini L, Piepoli M.F., Coats AJ, Zardini P, Poole-Wilson PA, Anker SD Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. Journal of Cardiac Failure 2004; 10:421-6.
11. Cicoira M, Kalra PR, Anker SD Growth hormone resistance in chronic heart failure and its therapeutic implications. Journal of Cardiac Failure 2003; 9:219-26.
12. Cicoira M, Zanolla L, Franceschini L., Rossi A, Golia G, Zamboni M., Tosoni P, Zardini P. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. Journal of the American College of Cardiology 2001; 37:2080-5.
13. Coats AJS. The "muscle hypothesis" of chronic heart failure. Journal of Molecular and Cellular Cardiology 1996; 28:2255-62.
14. Cunha TF, Bacurau AV, Moreira JB, Paixão NA, Campos JC, Ferreira JC, Leal ML, Negrão CE, Moriscot AS, Wisløff U, Brum PC. Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure. PLoS ONE 2012; 7:e41701.
15. Dalla Libera L., Sabbadini R, Renken C., Ravara B, Sandri M, Betto R., Angelini A, Vescovo G. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. Journal of Molecular and Cellular Cardiology 2001; 33:1871-8.
16. Douglas RG, Gluckman PD, Breier BH, McCall JL, Parry B, Shaw JH. Effects of recombinant IGF-I on protein and glucose metabolism in rTNF-infused lambs. American Journal of Physiology 1991; 261(5 Pt 1):E606-12.
17. Drexler H, Riede U, Münzel T, König H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 1992; 85:1751-9.
18. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. Journal of Cachexia, Sarcopenia and Muscle 2011; 2:143-51.
19. Evans WJ, Morley JE, Argilés J, Bales C., Baracos V, Guttridge D, Jatoi A., Kalantar-Zadeh K, Lochs H, Mantovani G., Marks D, Mitch WE, Muscaritoli M, Najand A., Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A., Schuster M, Thomas D, Wolfe R., Anker SD. Cachexia: a new definition. Clinical Nutrition 2008; 27:793-9.
20. Fanzani AM, Conraads VM, Penna F, Martinet F. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. Journal of Cachexia, Sarcopenia and Muscle 2012; 3:163-79.
21. Fearon K, Evans WJ, Anker SD Myopenia - a new universal term for muscle wasting. Journal of Cachexia, Sarcopenia and Muscle 2011; 2:1-3.
22. Ferrari R, Bachetti T, Confortini R., Opasich C, Febo O, Corti A., Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479-86.
23. Fülster S., Tacke M, Sandek A., Ebner N, Tschöpe C, Doehner W, Anker SD, von Haehling S. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). European Heart Journal 2013; 34:512-9.
24. Garcia-Martinez C., Llovera M, Agell N., Lopez-Soriano FJ, Argiles JM Ubiquitin gene expression in skeletal muscle is increased during sepsis: involvement of TNF-alpha but not IL-1. Biochemical and Biophysical Research Communications 1995; 217:839-944.
25. Gielen S, Adams V, Möbius-Winkler S, Linke A, Erbs S, Yu J, Kempf W, Schubert A, Schuler G, Hambrecht R. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. Journal of the American College of Cardiology 2003; 42:861-8.
26. Gielen S, Sandri M, Kozarez I., Kratzsch J, Teupser D, Thiery J., Erbs S, Mangner N, Lenk K., Hambrecht R, Schuler G, Adams V. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 2012; 125:2716-27.
27. Gilson H, Schakman O, Kalista S., Lause P, Tsuchida K, Thissen JP Follistatin induces muscle hypertrophy through satellitecell proliferation and inhibition of both myostatin and activin. American Journal of Physiology Endocrinology and Metabolism 2009; 297:E157-64.
28. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proceedings of the National Academy of Sciences of the United States of America 2001; 98:14440-5.
29. Hambrecht R, Schulze PC, Gielen S, Linke A., Möbius-Winkler S, Erbs S, Kratzsch J, Schubert A, Adams V, Schuler G. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. European Journal of Cardiovascular Prevention and Rehabilitation 2005; 12:401-6.
30. Hambrecht R, Schulze PC, Gielen S, Linke A., Möbius-Winkler S, Yu J, Jü KJ, Baldauf G, Busse MW, Schubert A, Adams V, Schuler G. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. Journal of the American College of Cardiology 2002; 39:1175-81.
31. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, Coats AJ. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. Journal of the American College of Cardiology 1997; 30:1758-64.
32. Hasselgren PO, Alamdari N, Aversa Z., Gonnella P, Smith IJ, Tizio S. Corticosteroids and muscle wasting: role oftranscription factors, nuclearcofactors, and hyperacetylation. Current Opinion in Clinical Nutrition and Metabolic Care 2010; 13:423-8.
33. Heineke J, Auger-Messier M, Xu J., Sargent M, York A, Welle S, Molkentin JD. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010; 121:419-25.
34. Hikida RS, Van Nostran S, Murray JD, Staron R.S., Gordon SE, Kraemer WJ Myonuclear loss in atrophied soleus muscle fibers. Anatomical Record 1997; 247:350-4.
35. Hsieh PL, Wu YT, Chao WJ Effects of exercise training in heart transplant recipients: a meta-analysis. Cardiology 2011; 120:27-35.
36. Kadoglou NP, Vrabas IS, Kapelouzou A, Lampropoulos S., Sailer N, Kostakis A, Liapis C.D., Angelopoulou N. The impact of aerobic exercise training on novel adipokines, apelin and ghrelin, in patients with type 2 diabetes. Medical Science Monitor 2012; 18:CR290-5.
37. Kiilavuori K, Näveri H, Leinonen H., Härkönen M. The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. European Heart Journal 1999; 20:456-64.
38. Larsen AI, Lindal S, Aukrust P, Toft I, Aarsland T, Dickstein K. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure, Correlation between skeletal muscle alterations, cytokines and exercise capacity. International Journal of Cardiology 2002; 83:25-32.
39. Lenk K, Erbs S, Höllriegel R, Beck E., Linke A, Gielen S, Winkler S.M., Sandri M., Hambrecht R, Schuler G, Adams V. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. European Journal of Preventive Cardiology 2012; 19:404-11.
40. Lenk K, Schur R, Linke A., Erbs S, Matsumoto Y, Adams V., Schuler G. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. European Journal of Heart Failure 2009; 11:342-8.
41. Lipkin DP, Jones DA, Round J.M., Poole-Wilson PA. Abnormalities of skeletal muscle in patients with chronic heart failure. International Journal of Cardiology 1988; 18:187-95.
42. Llovera M, Garcia-Martinez C, Agell N., Lopez-Soriano FJ, Authier FJ, Gherardi R.K., Argiles JM Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. International Journal of Molecular Medicine 1998; 2:69-73.
43. Mak RH, Ikizler AT, Kovesdy C.P., Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. Journal of Cachexia, Sarcopenia and Muscle 2011; 2:9-25.
44. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy X-ray absorptiometry for total-body and regional bonemineral and soft-tissue composition. American Journal of Clinical Nutrition 1990; 51:1106-12.
45. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, FonsecaC, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, StepinskaJ, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document Reviewers, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 2012; 14:803-69.
46. McPherron AC, Lawler AM, Lee SJ Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387:83-90.
47. Morley JE, Abbatecola AM, Argiles J.M., Baracos V., Bauer J, Bhasin S, Cederholm T., Coats AJ, Cummings SR, Evans WJ, Fearon K, Ferrucci L., Fielding RA, Guralnik JM, Harris TB, Inui A, Kalantar-Zadeh K, Kirwan B.A., Mantovani G., Muscaritoli M, Newman AB, Rossi-Fanelli F, Rosano GM, Roubenoff R, Schambelan M, Sokol GH, Storer TW, Vellas B, von Haehling S, Yeh SS, Anker SD, Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus. Journal of the American Medical Directors 2011; 12:403-9.
48. Muiller-Hocker J. Morphologie, Cytochemie und Immunhistochemie des Cytochrom-c-oxidase-Mangels. Verhandlungen der Deutschen Gesellschaft fur Pathologie 1988; 72:552-65.
49. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110:3674-9.
50. O'Connor C.M., Whellan DJ, Lee K.L., Keteyian SJ, Cooper LS, Ellis SJ, Leifer E.S., Kraus WE, Kitzman DW, Blumenthal JA, Rendall D.S., Miller NH, Fleg JL, Schulman KA, McKelvie R.S., Zannad F., Pinã IL, HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial. JAMA 2009; 301:1439-50.
51. Ochi E, Nakazato K, Ishii N. Muscular hypertrophy and changes in cytokine production after eccentric training in the rat skeletal muscle. Journal of Strength and Conditioning 2011; 25:2283-92.
52. Onder G, Penninx BW, Balkrishnan R, Fried L.P., Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002; 359:926-30.
53. Osterziel KJ, Strohm O, Schuler J., Friedrich M, Hänlein D, Willenbrock R., Anker SD, Poole-Wilson PA, Ranke MB, Dietz R. Randomised, double-blind, placebocontrolled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351:1233-7.
54. Piepoli MF, Conraads V, Corrà U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. a consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. European Journal of Heart Failure 2011; 13:347-57.
55. Pires-Oliveira M., Maragno AL, Parreiras-e-Silva LT, Chiavegatti T, Gomes MD, Godinho RO. Testosterone represses ubiquitin ligases atrogin-1 and Murf-1 expression in an androgen-sensitive rat skeletal muscle in vivo. Journal of Applied Physiology 2010; 108:266-73.
56. Plinta R, Olszanecka-Glinianowicz M, Drosdzol-Cop A, Chudek J, Skrzypulec-Plinta V. The effect of three-month preseason preparatory period and short-term exercise on plasma leptin, adiponectin, visfatin, and ghrelin levels in young female handball and basketball players. Journal of Endocrinological Investigation 2012; 35:595-601.
57. Rauchhaus M, Doehner W, Francis D.P., Davos C., Kemp M, Liebenthal C, Niebauer J., Hooper J, Volk HD, Coats AJ, Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-7.
58. Reid MB, Li YP Tumor necrosis factor-a and muscle wasting: a cellular perspective. Respiratory Research 2001; 2:269-72.
59. Rosenberg IH. Sarcopenia: origins and clinical relevance. Clinics in Geriatric Medicine 2011; 27:337-9.
60. Roubenoff R, Heymsfield SB, Kehayias JJ, Cannon JG, Rosenberg IH. Standardization of nomenclature of body composition in weight loss. American Journal of Clinical Nutrition 1997; 66:192-6.
61. Ryall JG, Lynch GS The potential and the pitfalls of beta-adrenoceptor agonists forthe management of skeletal muscle wasting. Pharmacology & Therapeutics 2008; 120:219-32.
62. Sajjadi FG, Takabayashi K, Foster A.C., Domingo RC, Firestein GS Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. Journal of Immunology 1996; 156:3435-42.
63. Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. Journal of Cachexia, Sarcopenia and Muscle 2012; 3:77-94.
64. Santos RV, Viana VA, Boscolo R.A., Marques VG, Santana MG, Lira FS, Tufik S, de Mello MT. Moderate exercise training modulates cytokine profile and sleep in elderly people. Cytokine 2012; 60:731-5.
65. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skeletal Muscle 2011; 1:4.
66. Schols AM, Gosker HR The pathophysiology of cachexia in chronic obstructive pulmonary disease. Current Opinion in Supportive and Palliative Care 2009; 3:282-7.
67. Schulze PC, Späte U. Insulin-like growth factor-1 and muscle wasting in chronic heart failure. International Journal of Biochemistry and Cell Biology 2005; 37:2023-35.
68. Smart NA, Larsen AI, Le Maitre JP, Ferraz AS Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure. Cardiology Research and Practice 2011; 2011:532-620.
69. Smart NA, Steele M. The effect of physical training on systemic proinflammatory cytokine expression in heart failure patients: a systematic review. Congestive Heart Failure 2011; 17:110-4.
70. Springer J, Adams V, Anker SD Myostatin: regulator of muscle wasting in heart failure and treatment target for cardiac cachexia. Circulation 2010; 121:354-6.
71. Sukhanov S, Semprun-Prieto L, Yoshida T., Michael Tabony A, Higashi Y, Galvez S., Delafontaine P. Angiotensin II, oxidative stress and skeletal muscle wasting. American Journal of the Medical Sciences 2011; 342:143-7.
72. Sullivan MJ, Green HJ, Cobb FR Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990; 81: 518-27.
73. Sumukadas D, Struthers AD, McMurdo ME Sarcopenia - a potential target for Angiotensin-converting enzyme inhibition? Gerontology 2006; 52:237-42.
74. Tabony AM, Yoshida T, Galvez S., Higashi Y, Sukhanov S, Chandrasekar B., Mitch WE, Delafontaine P. Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension 2011; 58:643-9.
75. Toth MJ, Ward K, van der Velden J, Miller MS, Vanburen P, Lewinter MM, Ades PA. Chronic heart failure reduces Akt phosphorylation in human skeletal muscle: relationship to muscle size and function. Journal of Applied Physiology 2011; 110:892-900.
76. Tsarouhas K, Tsitsimpikou C, Haliassos A., Georgoulias P, Koutsioras I, Kouretas D., Kogias J, Liosis I, Rentoukas E., Kyriakides Z. Study of insulin resistance, TNF-α, total antioxidant capacity and lipid profile in patients with chronic heart failure under exercise. In Vivo 2011; 25:1031-7.
77. Vaughan VC, Martin P, Lewandowski PA Cancer cachexia: impact, mechanisms and emerging treatments. Journal of Cachexia, Sarcopenia and Muscle 2012., http://dx.doi.org/10.1007/s13539-012-0087-1 (in press).
78. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology 2008; 154:557-68.
79. Vescovo G, Volterrani M, Zennaro R., Sandri M, Ceconi C, Lorusso R., Ferrari R, Ambrosio GB, Dalla Libera L. Apoptosis in the skeletal muscle of patients with heart failure: investigation ofclinical and biochemical changes. Heart 2000; 84:431-7.
80. von Haehling S., Genth-Zotz S, Anker S.D., Volk HD Cachexia: a therapeutic approach beyond cytokine antagonism. International Journal of Cardiology 2002; 85(September (1)):173-83.
81. von Haehling S., Lainscak M, Doehner W., Ponikowski P, Rosano G, Jordan J, Rozentryt P, Rauchhaus M, Karpov R, Tkachuk V, Parfyonova Y, Zaritskey AY, Shlyakhto EV, Cleland JG, Anker SD. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Journal of Cachexia, Sarcopenia and Muscle 2010; 1:187-94.
82. von Haehling S., Morley JE, Anker SD From muscle wasting to sarcopenia and myopenia: update 2012. Journal of Cachexia, Sarcopenia and Muscle 2012; 3: 213-7.
83. von Haehling S. The muscle in dire straits: mechanisms of wasting in heart failure. Circulation 2012; 125:2686-8.
84. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. American Journal of Physiology Endocrinology and Metabolism 2008; 295:E785-97.
85. Williams A, Sun X, Fischer J.E., Hasselgren PO The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 1999; 126:744-9.
86. Witham MD, Sumukadas D, McMurdo ME ACE inhibitors for sarcopenia - as good as exercise training? Age and Ageing 2008; 37:363-5.
87. Woodrow G. Body composition analysis techniques in adult and pediatric patients: how reliable are they? How useful are they clinically? Peritoneal Dialysis International 2007; 27(Suppl. 2):S245-9.